🏛️ Verified NIH Record • Updated 2026-08-26

Pediatric Long-Term Follow-up and Rollover Study (NCT03975829)

An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)

🔵 Active, Not Recruiting Phase4 💊 Investigational Drug / Biologic Sponsor: Novartis Pharmaceuticals

🩺 Plain-English Summary (8th-Grade Level)

A roll-over study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.

Who can join: Review the eligibility criteria below.

Location: Phoenix Children s Hospital — Phoenix, Arizona

Age range: 1 Year to 99 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (54 Sites)

Showing the first 25 of 54 sites.

  • Phoenix Children s Hospital — Phoenix, Arizona
  • Childrens National Hospital — Washington D.C., District of Columbia
  • Nicklaus Childrens Hospital — Miami, Florida
  • Indiana Uni School of Medicine — Indianapolis, Indiana
  • Johns Hopkins Hospital — Baltimore, Maryland
  • Dana Farber Cancer Institute — Boston, Massachusetts
  • University of Minnesota — Minneapolis, Minnesota
  • Memorial Sloan Kettering Cancer Ctr — New York, New York
  • Cinn Children Hosp Medical Center — Cincinnati, Ohio
  • St Jude Childrens Research Hospital — Memphis, Tennessee
  • Texas Childrens Hospital — Houston, Texas
  • Novartis Investigative Site — CABA, Buenos Aires
  • Novartis Investigative Site — Darlinghurst, New South Wales
  • Novartis Investigative Site — Parkville, Victoria
  • Novartis Investigative Site — Brussels,
  • Novartis Investigative Site — Barretos, São Paulo
  • Novartis Investigative Site — São Paulo, São Paulo
  • Novartis Investigative Site — São Paulo, São Paulo
  • Novartis Investigative Site — Vancouver, British Columbia
  • Novartis Investigative Site — Toronto, Ontario
  • Novartis Investigative Site — Montreal, Quebec
  • Novartis Investigative Site — Brno,
  • Novartis Investigative Site — Prague,
  • Novartis Investigative Site — Copenhagen,
  • Novartis Investigative Site — Tampere, Finland

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All Diffuse Astrocytoma clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗